Lloyds Shares Gain After Bank Buyback and BoE Rate View

Lloyds Shares Gain After Bank Buyback and BoE Rate View

June 16, 2026

London, June 16, 2026, 11:05 BST

  • Lloyds Banking Group traded at 103.40p on the buy side and 103.35p to sell in delayed London dealing, up 0.80p, a gain of 0.78%. Lloyds Bank Investments
  • Lloyds bought back 5 million shares on June 15 at an average price of 103.0013p per share. The bank said it will cancel the shares. Lloyds Bank Investments
  • Bank of England is set to announce its next rates decision on June 18. Every one of the 65 economists in a Reuters poll expects the Bank Rate to stay put at 3.75%. Reuters

Lloyds Banking Group plc rose in London on Tuesday, gaining 0.80p, or 0.78%, to finish at 103.40p on the bid and 103.35p offered. The stock changed hands between 102.65p and 104.05p. Lloyds is trading below its 52-week high of 112.60p, though it’s off the lows of 73.54p set this year. Investors are focused on share buybacks, the last round of results, and moves from the Bank of England. Lloyds Bank Investments

Lloyds did another share buyback. The bank said in a June 16 RNS it bought 5 million ordinary shares on June 15 from Goldman Sachs International, paying prices from 102.15p to 103.9p each. These shares will be cancelled, trimming the share count and possibly boosting earnings per share. The operating numbers are unchanged. Lloyds Bank Investments

Lloyds is right in the UK rates mix for banks. The bank relies on UK mortgages, deposits, and consumer credit—so the story turns on where rates go next. Net interest margin is still the headline number for profit. Reuters said in its latest poll that all 65 economists expect the Bank of England to keep Bank Rate at 3.75% on June 18. Nearly 40% see at least one more hike before year-end. Banks could gain if deposit costs hold, but longer higher rates put pressure on loan growth and borrowers. Reuters

Lloyds posted Q1 results showing buyers are still on board. Statutory pre-tax profit rose to £2.0 billion for the quarter ended March 31, up from £1.5 billion a year before. Underlying net interest income gained 8% to £3.6 billion, with net interest margin at 3.17%. CEO Charlie Nunn cited “sustained strength in financial performance” and restated 2026 targets. Lloyds kept its goals: underlying net interest income above £14.9 billion, cost-to-income ratio below 50%, return on tangible equity over 16%, and CET1 ratio near 13%. CET1 is a regulatory capital metric. EQS News

Lloyds still trades as a UK rates and capital return play, with steady structural hedge income, some loan growth, buybacks, and a 3.56% dividend yield, according to the market page. Back in April, Citi boosted its rating to “buy” and upped the target price to 114p from 106p. The bank also made Lloyds one of its top European picks for rising reinvestment yields. Lloyds Bank Investments

The bearish call is that Lloyds has priced in most positives after a big run this year, while risks still hang over the shares from the UK housing market, bad loans, political pressure on profits, and the open car-finance compensation fight. The bank holds a £1.95 billion motor finance provision. Reports say legal challenges could mean car finance payouts drag on until 2027. With the latest numbers, Lloyds trades at levels that look fair to maybe a touch cheap to investors focused on UK bank dividends and buybacks. Still, it’s not low-risk. The Bank of England’s June 18 meeting and Lloyds’ half-year results are likely to drive the narrative more than Tuesday’s minor share move. Lloyds Bank Investments

Stock Market Today

  • Genus Shares Rise on China JV and PRP Program Ahead of September Earnings
    June 16, 2026, 6:41 AM EDT. Genus plc shares rose about 0.7%-0.9% in London trade, outperforming the FTSE 250 index. Investor interest centers on Genus's China joint venture (JV) expected to contribute nearly £100 million in Q4 and regulatory progress with its PRRS-resistant pig (PRP) gene-editing program. Institutional investor JNE Partners LLP increased its voting stake above 5%, signaling confidence. Despite a strong H1 with a 38% rise in adjusted operating profit to £55.8 million, valuation at 26.63 times earnings and regulatory risks for PRP in key markets temper bullish sentiment. Analysts see room for share gains with a median 12-month price target of 3,200p, but highlight biotech regulatory uncertainties and market volatility. Full-year results are due September 10.